Matinas Biopharma Holdings Inc.

Matinas Biopharma Holdings Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Matinas Biopharma Holdings Inc. is not a good value stock. Matinas Biopharma Holdings Inc. is not a good growth stock. Matinas Biopharma Holdings Inc. is not very popular among insiders. Matinas Biopharma Holdings Inc. is a mediocre stock to choose.
Log in to see more information.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on enabling t...
MTNB Fundamental Data by TradingView

News

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Globe Newswire Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled...\n more…

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Globe Newswire BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...\n more…

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Globe Newswire BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...\n more…

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Globe Newswire Discussion and Q&A on June 18th to include a review of the antifungal treatment landscape, the advantages of MAT2203 versus IV-amphotericin B and the MAT2203 market opportunityBEDMINSTER, N.J., June...\n more…

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Globe Newswire BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...\n more…

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Globe Newswire Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO...\n more…